Navigation Links
NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance for 2011
Date:8/3/2011

million."

NxStage reported a net loss of $5.6 million, or ($0.10) per share, for the second quarter of 2011 compared with a net loss of $8.3 million, or ($0.17) per share, for the second quarter of 2010.

For the second quarter of 2011, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses of $1.8 million, compared with an Adjusted EBITDA loss of $0.2 million in the second quarter of 2010.  (See the exhibits for a reconciliation of this non-GAAP measure.)

NxStage announced that it recently concluded its renegotiation of its United States home market agreement with one of its largest customers and signed an amendment to that agreement, extending the term to December 31, 2012, and up to one additional year thereafter.  The amended agreement covers the use of NxStage's products for home hemodialysis.

Separately, NxStage announced that pursuant to its agreement with DaVita, for the period ended June 30, 2011, DaVita achieved System One home patient growth targets that entitled it to become vested in warrants to purchase 250,000 shares of NxStage common stock.  

Guidance:

For the third quarter of 2011, the Company is forecasting revenue to be within a range of $53.5 to $54.5 million.  At this revenue level, the Company would expect a net loss in the range of $5.0 to $6.0 million or ($0.09) to ($0.11) per share, and Adjusted EBITDA in the range of $1.0 to $2.0 million for the third quarter of 2011.  

Supported by its strong performance in the first half of 2011, the Company now anticipates revenue for the 2011 fiscal year to be in a range of $210 to $215 million, compared with its prior guidance for revenues to be in a range of $205 to $213 million.  The Company is maintaining its guidance for a net loss in the range of $19 to $23 million or ($0.36) to ($0.43) per share, and
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA
2. NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner
3. NxStage Announces Second Quarter 2011 Investor Conference Schedule
4. NxStage® Supports Initiative by Patient Advocacy Groups to Educate Policymakers about the Benefits of Frequent Home Hemodialysis
5. NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand
6. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
7. NxStage® Names Michael Miller, Jr. President, International
8. NxStage® to Report First Quarter Fiscal 2011 Financial Results
9. Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines
10. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
11. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... the basis of test type, technology, product, and ... register the highest growth rate in the newborn ... This high growth is attributed to various nations ... is a fundamental instrument used for expanded newborn ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... 23, 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... of Phase 1 clinical trial testing of its HIV/AIDS vaccine ... of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 ... The Journal of Infectious Diseases . A ...
... 23, 2011 Cardiogenesis Corporation (Pink Sheets: CGCP ... fourth quarter and full-year ended December 31, 2010 on Wednesday, ... its Executive Chairman, and William R. Abbott, its Senior Vice ... call that day at 5:00 p.m. Eastern time (2:00 p.m. ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Cardiogenesis Corporation to Report 2010 Fourth Quarter and Full-Year Results on March 9th 2
(Date:10/30/2014)... Jacksonville, FL (PRWEB) October 30, 2014 ... non-profit offering therapeutic horseback riding to special needs individuals ... Annual Round-Up on Saturday, November 15 from 10-2:00 p.m. ... fun event is open to the public and is ... programs. , Admission to the HSS Round-Up is ...
(Date:10/30/2014)... California (PRWEB) October 30, 2014 REV'D ... bars are now available through a unique service called, ... site designed to empower the everyday athlete. The Feed ... best athletes and created a system to pass that ... to see REV’D® is now available on The Feed!” ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
(Date:10/30/2014)... News) -- Scientists who used stem cells to create ... could provide a new way to learn more about ... team used human pluripotent stem cells -- which can ... to grow the functional miniature stomachs, to study infection ... of ulcers and stomach cancer. The miniature stomachs ...
(Date:10/30/2014)... -- Many U.S. colleges have indoor tanning salons ... the risk for skin cancer, researchers report. ... women, so colleges should adopt tanning-free policies, to ... "Public health efforts are needed to raise university ... that indoor tanning poses to young adults in ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... University of Michigan Health System-led team of researchers has found ... the most serious complications in patients with leukemia, lymphoma and ... blood-forming cells. Known as a hematopoietic stem cell transplant, ... from a matched donor who is either a family member ...
... Research Hospital scientists advances a strategy for taming the ... and other medications that work by disrupting the activity ... small molecule developed at St. Jude. In this study, ... blocked the activity of genes in a cell signaling ...
... endoprosthetic joint replacement in patients with osteoarthritis. Henning ... current issue of Deutsches rzteblatt International ... cartilage defects often develop subsequent to injury or ... overview of currently available medical and surgical therapeutic ...
... Magnetic resonance imaging (MRI) is an established technique which over ... professionals to study biological phenomena in the body without using ... by normal MRI are, to put it simply, pictures of ... up of water. MRI produces images of the hydrogen nuclei ...
... HealthDay Reporter , THURSDAY, Oct. 20 (HealthDay ... have many more accidents than adults have zeroed in ... braking late, swerving abruptly and other common new-driver mistakes. ... likely and leave less time to react to hazards, ...
... of people who were suicidal has highlighted the main challenges they ... and decide what they should do about it. The ... College of Medicine and Dentistry, supported by Devon NHS Partnership Trust ... published in the British Medical Journal on 22nd October ...
Cached Medicine News:Health News:Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 3Health News:New instrument helps researchers see how diseases start and develop in minute detail 2Health News:Teen Drivers Prone to 'G-Force' Errors, Researchers Say 2Health News:Teen Drivers Prone to 'G-Force' Errors, Researchers Say 3Health News:Study highlights issues faced by friends and family of the suicidal 2
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Medicine Products: